Maverick Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Maverick Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,861	Closed	-$529K	–	570
2021 Q3	$529K	Sell	5,861 -4,311	-42%	-$390K	0.01%	435
2021 Q2	$970K	Sell	10,172 -1,001	-9%	-$104K	0.01%	307
2021 Q1	$1.27M	Buy	+11,173	New	+$1.52M	0.01%	209

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital's RARE Position: Q4 2021 in Review

Maverick Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 5,861 shares — an estimated $529K sold.

Maverick Capital first reported a position in RARE in Q1 2021 and held it in 3 quarters. The position peaked at $1.27M in Q1 2021. 234 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

Maverick Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
Maverick Capital sold 5,861 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $529K.
Maverick Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 3 quarters.
Maverick Capital's Ultragenyx Pharmaceutical position peaked at $1.27M in Q1 2021.
234 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.